Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01552603 · ClinicalTrials.gov registry record · Phase 2
Artificial Pancreas Control System in an Inpatient Setting
A Phase 2 study, sponsored by Legacy Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01552603: Completed Phase 2 study, sponsored by Legacy Health System.
NCT01552603 is a Phase 2 study that has completed, run by Legacy Health System. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01552603, a Phase 2 study, has completed, sponsored by Legacy Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to verify an automated system of blood glucose control in Type I Diabetics. The automated system consists of the investigational Artificial Pancreas Control software (APC), two blood glucose sensors, and two hormone pumps, one for delivering insulin to lower blood sugar, and the second for delivering glucagon to raise blood sugar. The blood glucose sensors relays information to the Artificial Pancreas software, which uses the Adaptive Proportional Device algorithm to determine the rate of insulin and glucagon infusion by the hormone pumps. In prior studies, the Adaptive Proportional Device algorithm has been verified, but required manual input into the computer and hormone pumps. This study differs in that it uses a fully automated system under the control of the Artificial Pancreas Control software. The importance of this change is that it is the next step to enable outpatient use of automated, closed loop blood glucose control.
Primary Outcome
Mean percent of time venous blood glucose was sampled between 70-180 mg/dl
Interventions
- DEVICE Artificial Pancreas Control Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01552603 record still lists
NCT01552603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Artificial Pancreas Control Software is the first listed.
NCT01552603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01552603 about?
NCT01552603 is a clinical study titled "Artificial Pancreas Control System in an Inpatient Setting". The purpose of this study is to verify an automated system of blood glucose control in Type I Diabetics. The automated system consists of the investigational Artificial Pancreas Control software (APC), two blood glucose sensors, and two hormone pumps, one for delivering insulin to lower blood sugar,...
What is the current status of trial NCT01552603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01552603?
The interventions under investigation include: Artificial Pancreas Control Software (DEVICE).
Who is sponsoring clinical trial NCT01552603?
This trial is sponsored by Legacy Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01552603's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia